Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors
/PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced interim data from...
Source: prnewswire.com